Sign in

CIK 0001178670 · Large accelerated filer

ALNYLAM PHARMACEUTICALS, INC.

Sign in to watch
Ticker
ALNY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
operating
EIN
770602661
Phone
(617) 551-8200
Business address
675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
Former names
ALNYLAM PHARMACEUTICALS INC
Open-market buys, last 90 days
$543,126
in 2 filings
Open-market sales, last 90 days
$398,855
in 1 filing

Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-03-02 Greenstreet Yvonne Chief Executive Officer Sale −424 $328.71 $139K 100,255
2026-03-02 Greenstreet Yvonne Chief Executive Officer Sale −722 $329.71 $238K 99,533
2026-03-02 Greenstreet Yvonne Chief Executive Officer Sale −346 $330.85 $114K 99,187
2026-03-02 Greenstreet Yvonne Chief Executive Officer Sale −399 $331.93 $132K 98,788
2026-03-02 Greenstreet Yvonne Chief Executive Officer Sale −160 $332.64 $53K 98,628
2026-03-02 Greenstreet Yvonne Chief Executive Officer Grant or award · Stock Option (right to buy) +30,425 30,425
2026-03-02 Greenstreet Yvonne Chief Executive Officer Grant or award · Stock Price Performance Stock Unit +110,746 110,746
2026-02-27 Greenstreet Yvonne Chief Executive Officer Option exercise +5,921 91,583
2026-02-27 Greenstreet Yvonne Chief Executive Officer Option exercise · Restricted Stock Units −5,921 0
2026-02-27 Poulton Jeffrey V. EVP, Chief Financial Officer Option exercise +1,908 61,710
2026-02-27 Poulton Jeffrey V. EVP, Chief Financial Officer Option exercise · Restricted Stock Units −1,908 0
2026-02-27 Tanguler Tolga EVP, Chief Commercial Officer Option exercise +1,666 33,435
2026-02-27 Tanguler Tolga EVP, Chief Commercial Officer Option exercise · Restricted Stock Units −1,666 0
2026-02-27 Garg Pushkal EVP Chief R&D Option exercise 10b5-1 +1,908 26,756
2026-02-27 Garg Pushkal EVP Chief R&D Sale 10b5-1 −127 $328.92 $42K 26,629
2026-02-27 Garg Pushkal EVP Chief R&D Sale 10b5-1 −2,259 $330.73 $747K 24,370
2026-02-27 Garg Pushkal EVP Chief R&D Sale 10b5-1 −1,159 $331.49 $384K 23,211
2026-02-27 Garg Pushkal EVP Chief R&D Sale 10b5-1 −942 $332.48 $313K 22,269
2026-02-27 Garg Pushkal EVP Chief R&D Sale 10b5-1 −140 $334.39 $47K 22,129
2026-02-27 Garg Pushkal EVP Chief R&D Option exercise · Restricted Stock Units 10b5-1 −1,908 0

Page 9 of 41 · 816 trades